| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157584 | AZURITY | Benzimidazole derivative and use thereof |
May, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | AZURITY | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(1 year, 3 months from now) | |
| US9066936 | AZURITY | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(4 years from now) | |
| US9169238 | AZURITY | Solid pharmaceutical composition |
Feb, 2030
(6 years from now) | |
| US9387249 | AZURITY | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
Jul, 2031
(7 years from now) | |
Edarbyclor is owned by Azurity.
Edarbyclor contains Azilsartan Kamedoxomil; Chlorthalidone.
Edarbyclor has a total of 5 drug patents out of which 0 drug patents have expired.
Edarbyclor was authorised for market use on 20 December, 2011.
Edarbyclor is available in tablet;oral dosage forms.
Edarbyclor can be used as treatment of hypertension.
The generics of Edarbyclor are possible to be released after 01 July, 2031.
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
Market Authorisation Date: 20 December, 2011
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
EDARBYCLOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic